135 Results for "

CSF1R

" in MedChemExpress (MCE) Product Catalog:
Products (135)

135 Results for "CSF1R" in MCE Product Catalog:

  • Targets Recommended:
171
171 Publications Verification
Art. -Nr.: HY-16749A
CAS. Nr.: 2040295-03-0
Synonyms: PLX-3397 hydrochloride
Target:  

c-Fms c-Kit Apoptosis

Forschungsgebiete:  

Cancer

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity [1].
loading...
    loading...
171
171 Publications Verification
Art. -Nr.: HY-16749
CAS. Nr.: 1029044-16-3
Synonyms: PLX-3397
Target:  

c-Fms c-Kit Apoptosis

Forschungsgebiete:  

Cancer

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 [1] .
loading...
    loading...
101
101 Cited Publications
Art. -Nr.: HY-114153A
Reinheit:  99.88%
Target:  

c-Fms

PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 hemifumarate demonstrates desirable PK properties in varies animals [1] .
loading...
    loading...
101
101 Cited Publications
Art. -Nr.: HY-114153
CAS. Nr.: 1303420-67-8
Reinheit:  99.79%
Target:  

c-Fms

PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 is an ideal choose for microglia function research in healthy or diseased states. PLX5622 has been verified by MedChemExpress, which demonstrates desirable microglia depletion efficiency in mice. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm [1] .
loading...
    loading...
43
43 Cited Publications
Art. -Nr.: HY-12768
CAS. Nr.: 953769-46-5
Reinheit:  99.83%
Synonyms: BLZ945
Target:  

c-Fms

Forschungsgebiete:  

Infection Neurological Disease Cancer

Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research [1] .
loading...
    loading...
43
43 Cited Publications
Art. -Nr.: HY-12768A
CAS. Nr.: 2222138-31-8
Reinheit:  99.43%
Synonyms: BLZ945 hydrochloride
Target:  

c-Fms

Forschungsgebiete:  

Cancer

Sotuletinib (BLZ945) hydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib hydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research. [1].
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-50905
CAS. Nr.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Forschungsgebiete:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [1] .
loading...
    loading...
9
9 Cited Publications
Art. -Nr.: HY-114153C
CAS. Nr.: 1303420-67-8
Target:  

c-Fms

Forschungsgebiete:  

Neurological Disease

PLX5622 in AIN-76A Diet (1200 ppm) contains 1200 mg of PLX5622 (HY-114153) per Kg of AIN-76 diet and it can be used for microglia clearance. PLX5622 in AIN-76A Diet (1200 ppm) is ideal choose for microglia function research in healthy/diseased states. PLX5622 in AIN-76A Diet (1200 ppm) has been verified by MedChemExpress (MCE).The color of PLX5622 in AIN-76A Diet (1200 ppm) provided by MCE is blue. Meanwhile, MCE will provide an equal amount of PLX5622-Free AIN-76A Diet (no added pigments) as a complimentary offering, which is used for the control group.
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-10408
CAS. Nr.: 623142-96-1
Reinheit:  99.51%
Target:  

c-Fms VEGFR c-Kit PDGFR

Forschungsgebiete:  

Inflammation/Immunology

Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction [1].
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-10204
CAS. Nr.: 728033-96-3
Reinheit:  98.57%
Target:  

c-Kit VEGFR c-Fms Apoptosis

Forschungsgebiete:  

Cancer

OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity [1].
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-117244
CAS. Nr.: 1041852-85-0
Reinheit:  99.57%
Target:  

c-Fms

Forschungsgebiete:  

Cancer

AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-109086
CAS. Nr.: 1142363-52-7
Reinheit:  98.80%
Synonyms: JNJ-40346527; JNJ-527
Target:  

c-Fms

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively [1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research [1] .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-109190
CAS. Nr.: 1619931-27-9
Reinheit:  99.94%
Synonyms: GB002; PK10571
Target:  

PDGFR c-Fms c-Kit

Forschungsgebiete:  

Cardiovascular Disease

Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension [1] .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-P99259
CAS. Nr.: 1613144-80-1
Synonyms: FPA 008; Anti-Human CSF1R Recombinant Antibody

Target:  

c-Fms

Forschungsgebiete:  

Inflammation/Immunology Cancer

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research [1] .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-101774
CAS. Nr.: 2095849-04-8
Reinheit:  98.11%
Target:  

c-Fms

Forschungsgebiete:  

Cancer

CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-101768
CAS. Nr.: 1802929-43-6
Reinheit:  99.78%
Target:  

FGFR c-Fms

Forschungsgebiete:  

Cancer

PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively [1].
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-139990
CAS. Nr.: 2760584-90-3
Reinheit:  98.26%
Target:  

c-Fms

Forschungsgebiete:  

Cancer

CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity [1].
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-P72948
Reinheit:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CSF1R; CSF-1R; Prev. FMS; Macrophage Colony Stimulating Factor I Receptor; C-FMS; Colony Stimulating Factor Receptor; CD115; Receptor Protein-Tyrosine Kinase; CSFR; FMS Proto-Oncogene; McDonough Feline Sarcoma Viral (V-Fms) Oncogene Homolog; BANDDOS; Macr
Species:  
Human
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-132166
CAS. Nr.: 2590556-80-0
Reinheit:  99.47%
Synonyms: M4205; IDRX-42
Target:  

c-Kit PDGFR c-Fms FLT3 Src

Forschungsgebiete:  

Cancer

Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and LCK, with an IC50s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models [1].
loading...
    loading...
Art. -Nr.: HY-P990125
Anti-Mouse (CSF1R/CD115) Antibody (AFS98) is an anti-mouse CSF1R IgG2a antibody inhibitor derived from rats. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) inhibits M-CSF-dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) can be used for the researches of inflammation, metabolic disease, cardiovascular disease and neurological disease, such as such as stroke, diabetes and arthritis [1] .
loading...
    loading...